Keryx Biopharmaceuticals
Part of Akebia Therapeutics
CompanyUnited States
Keryx Biopharmaceuticals develops 2 assets, the furthest approved (ferric citrate in hyperphosphatemia in dialysis-dependent chronic kidney disease). Mostly small molecule and other; based in the United States.
- 2
- Assets
- Furthest stage
- Approved
- 13
- Trials
- 11
- Signals
Pipeline
2Binds dietary phosphate in the gastrointestinal tract, reducing phosphate absorption and serum phosphorus levels.
Approved, Small molecule, hyperphosphatemia in dialysis-dependent chronic kidney disease, iron deficiency anemia in non-dialysis-dependent chronic kidney disease
Glycosaminoglycan mixture that enhances antithrombin and heparin cofactor II activity and supports endothelial glycocalyx integrity.
Phase 3, no development reported, Other, diabetic kidney disease, peripheral arterial obstructive disease
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms3
- Trials18
- Deals1
- Signals13
- Similar companies6